Clinical trial
Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid
NCT00295646 · Austrian Breast & Colorectal Cancer Study Group, Other · Completed
Key facts
| NCT number | NCT00295646 |
|---|---|
| Title | Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid |
| Official title | Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid, in Premenopausal, Hormone Receptor-positive Breast Cancer Patients (Stage I, II) |
| Lead sponsor | Austrian Breast & Colorectal Cancer Study Group, Other |
| Collaborators | AstraZeneca Industry Novartis Pharmaceuticals |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug, Other |
| Interventions | tamoxifen, anastrozole, zoledronic acid, goserelin |
| Enrollment | 1,803 |
| Start date | Jun 1, 1999 |
| Primary completion | Mar 27, 2008 |
| Completion | Jun 26, 2018 |
| First posted | Feb 24, 2006 |
| Last update posted | Mar 15, 2024 |
| Countries | Austria, Germany |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: